There are currently no manufacturer details available.
Share This Page
Oscient Pharmaceuticals Drugs
FACTIVE can be taken with or without food and should be swallowed whole with a liberal amount of liquid. The recommended dose of FACTIVE is 320 mg daily, according to the following table (Table 4).
The clinical decision regarding the use of a 5 or 7 day regimen should be guided by results of the initial sputum culture.Table 4. Recommended Dosage Regimen of FACTIVE INDICATION DOSE / DURATION *MDRSP: multi-drug resistant Streptococcus pneumoniae, includes isolates previously known as PRSP (penicillin-resistant Streptococcus pneumoniae), and are strains resistant to two or more of the following antibiotics: penicillin (MIC ≥2 µg/mL), 2nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines and trimethoprim/sulfamethoxazole. Acute bacterial exacerbation of chronic One 320 mg tablet daily for 5 days bronchitis Community-acquired pneumonia (of mild to moderate severity) due to known or suspected S. pneumoniae, H. influenzae, M. pneumoniae, or C. One 320 mg tablet daily for 5 days pneumoniae infection due to known or suspected MDRSP*, K. One 320 mg tablet daily for 7 days pneumoniae, or M. catarrhalis infection
The recommended dose and duration of FACTIVE should not be exceeded (see Table 2).
Use in Renally Impaired Patients: Dose adjustment in patients with creatinine clearance >40 mL/min is not required. Modification of the dosage is recommended for patients with creatinine clearance ≤40 mL/min. Table 5 provides dosage guidelines for use in patients with renal impairment.Table 5. Recommended Doses for Patients with Renal Impairment Creatinine Clearance (mL/min) Dose >40 See Usual Dosage ≤40 160 mg every 24 hours
Patients requiring routine hemodialysis or continuous ambulatory peritoneal dialysis (CAPD) should receive 160 mg every 24 hours.
When only the serum creatinine concentration is known, the following formula may be used to estimate creatinine clearance.
Women: 0.85 x the value calculated for men
Use in Hepatically Impaired Patients: No dosage adjustment is recommended in patients with mild (Child-Pugh Class A), moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment.
Use in Elderly: No dosage adjustment is recommended.
Sign Up for a Free Account